AN2 Therapeutics pauses Phase 3 enrollment in epetraborole trial after efficacy concern

AN2 Therapeutics, Inc.

Voluntary pause of Phase 3 enrollment in EBO-301 trial for treatment-refractory MAC lung disease.
Blinded aggregate analysis showed potentially lower than expected efficacy; no safety concerns cited.
Phase 2 part completed enrollment with 80 patients; Phase 3 had enrolled nearly 100 patients to date.
Enrolled patients allowed to continue; topline Phase 2 data expected summer 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.